Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial

International Journal of Stroke

Volumn 11, Issue 6, 2016, Pages 683-694

  Sprigg, Nikola ^a   Robson, Katie ^a   Bath, Philip ^a   Dineen, Robert ^a   Roberts, Ian ^a   Robinson, Tom ^a   Roffe, Christine ^a   Werring, David ^a   Al Shahi Salman, Rustam ^a   Pocock, Stuart ^a   Duley, Lelia ^a   England, Tim ^a   Whynes, David ^a   Ciccone, Alfonso ^a   Laska, Ann Charlotte ^a   Christensen, Hanne ^a   Ozturk, Serefnur ^a   Collins, Ronan ^a   Bereczki, Daniel ^a   Egea Guerrero, Juan Jose ^a   Law, Zhe Kang ^a   Czlonkowska, Anna ^a   Seiffge, David ^a   Beredzie, Maia ^a   more..

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Hyperacute intracerebral hemorrhage; placebo controlled; randomized trial; tranexamic acid

Indexed keywords

PLACEBO; TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

BOLUS INJECTION; BRAIN HEMORRHAGE; CLINICAL PROTOCOL; COGNITION; CONTROLLED STUDY; DEATH; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HOSPITAL READMISSION; HUMAN; INSTITUTIONALIZATION; INTERNATIONAL COOPERATION; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MOOD; MULTICENTER STUDY; NEUROLOGIC DISEASE; PARALLEL DESIGN; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; REVIEW; THROMBOEMBOLISM; AFFECT; CEREBRAL HEMORRHAGE; CLINICAL TRIAL; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; AFFECT; ANTIFIBRINOLYTIC AGENTS; CEREBRAL HEMORRHAGE; COGNITION; DISABILITY EVALUATION; HUMANS; LENGTH OF STAY; PATIENT READMISSION; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 84979946055     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1177/1747493016641960     Document Type: Review

References (31)

1. C.J.van AschM.J.LuitseG.J.RinkelI.van der TweelA.AlgraC.J.Klijn. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol2010; 9: 167–176.
2. T.SteinerJ.Bosel. Options to restrict hematoma expansion after spontaneous intracerebral hemorrhage. Stroke2010; 41: 402–409.
3. S.KazuiH.NaritomiH.YamamotoT.SawadaT.Yamaguchi. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke1996; 27: 1783–1787.
4. T.BrottJ.BroderickR.KothariW.BarsanT.TomsickL.Sauerbeck. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke1997; 28: 1–5.
5. Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2015. Epub ahead of print. DOI: 10.1161/STR.0000000000000069
6. Al-Shahi Salman R. Haemostatic drug therapies for acute spontaneous intracerebral haemorrhage. Cochrane Database Syst Rev 2009; 4: Art. No.: CD005951. DOI: 10.1002/14651858.CD005951.pub3
7. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23–32
8. CRASH-2 Collaborators (Intracranial Bleeding Study). Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ2011; 343: 3795.
9. S.ZehtabchiS.G.Abdel BakiL.FalzonD.K.Nishijima. Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis. Am J Emerg Med2014; 32: 1503–1509.
10. Y.DewanE.O.KomolafeJ.H.Mejia-MantillaP.PerelI.RobertsH.Shakur. CRASH-3—tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials2012; 13: 87.
11. Y.RoosG.RinkelM.VermeulenA.AlgraJ.van Gijn. Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage: a major update of a cochrane review. Stroke2003; 34: 2308–2309.
12. M.F.OjacastroM.P.TabuenaI.D.DulosR.P.Tabuena. Efficacy of tranexamic acid in reducing hematoma volume in patients with hypertensive intracerebral hemorrhage. Int J Stroke2008; 3: 197–198.
13. T.F.Y.SorimachiK.MoritaR.Tanaka. Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery2005; 57: 837–844.
14. N.SpriggC.J.RentonR.A.DineenY.KwongP.M.W.Bath. Tranexamic acid for spontaneous intracerebral hemorrhage: a randomized controlled pilot trial (ISRCTN50867461). J Stroke Cerebrovasc Dis2014; 23: 1312–1318.
15. Y.Roos. Editorial: tranexamic acid for traumatic brain injury. BMJ2011; 343: d3958.
16. A.MeretojaL.ChurilovB.C.CampbellR.I.AvivN.YassiC.Barras. The spot sign and tranexamic acid on preventing ICH growth—AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial. Int J Stroke2014; 9: 519–524.
17. A.F.FonvilleN.SamarasekeraA.HutchisonD.PerryY.B.RoosR.Al-Shahi Salman. Eligibility for randomized trials of treatments specifically for intracerebral hemorrhage: community-based study. Stroke2013; 44: 2729–2734.
18. R.Al-Shahi SalmanM.S.Dennis. Antiplatelet therapy may be continued after intracerebral hemorrhage. Stroke2014; 45: 3149–3150.
19. M.Saghaei. An overview of randomization and minimization programs for randomized clinical trials. J Med Signals Sensors2011; 1: 55–61.
20. National Institute of Health NIoNDaSSShwnngdNSSp, http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf (accessed September 2015)
21. F.I.MahoneyD.W.Barthel. Functional evaluation: the Barthel Index. Md State Med J1965; 14: 61–65.
22. P.M.BathK.R.LeesP.D.SchellingerH.AltmanM.BlandC.Hogg. Statistical analysis of the primary outcome in acute stroke trials. Stroke2012; 43: 1171–1178.
23. Euroqol Group. EuroQol—a new facility for the measurement of health-related quality of life. EuroQol Group Health Policy1990; 16: 199–208.
24. C.A.de JagerM.M.BudgeR.Clarke. Utility of TICS-M for the assessment of cognitive function in older adults. Int J Geriatr Psychiatry2003; 18: 318–324.
25. W.W.K.Zung. A self-rating depression scale. Arch Gen Psychiatry1965; 12: 63–70.
26. The Optimising Analysis of Stroke Trials (OAST) Collaboration. Should stroke trials adjust functional outcome for baseline prognostic factors?Stroke2009; 40: 888–894.
27. The CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet2011; 377: 1096–1101.
28. J.E.Delgado AlmandozA.J.YooM.J.StoneP.W.SchaeferJ.N.GoldsteinJ.Rosand. Systematic characterization of the computed tomography angiography spot sign in primary intracerebral hemorrhage identifies patients at highest risk for hematoma expansion. Stroke2009; 40: 2994–3000.
29. J.E.Delgado AlmandozA.J.YooM.J.StoneP.W.SchaeferA.OleinikH.B.Brouwers. The spot sign score in primary intracerebral hemorrhage identifies patients at highest risk of in-hospital mortality and poor outcome among survivors. Stroke2010; 41: 54–60.
30. A.EderiesA.DemchukT.ChiaD.J.GladstoneD.DowlatshahiG.BenDavit. Postcontrast CT extravasation is associated with hematoma expansion in CTA spot negative patients. Stroke2009; 40: 1672–1676.
31. J.C.HorrowD.F.Van RiperM.D.StrongK.E.GrunewaldJ.L.Parmet. The dose-response relationship of tranexamic acid. Anesthesiology1995; 82: 383–392.